Cargando…

SLC22A1-ABCB1 Haplotype Profiles Predict Imatinib Pharmacokinetics in Asian Patients with Chronic Myeloid Leukemia

OBJECTIVE: This study aimed to explore the influence of SLC22A1, PXR, ABCG2, ABCB1 and CYP3A5*3 genetic polymorphisms on imatinib mesylate (IM) pharmacokinetics in Asian patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: Healthy subjects belonging to three Asian populations (Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Onkar, Chan, Jason Yongsheng, Lin, Keegan, Heng, Charles Chuah Thuan, Chowbay, Balram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525665/ https://www.ncbi.nlm.nih.gov/pubmed/23272163 http://dx.doi.org/10.1371/journal.pone.0051771

Ejemplares similares

Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma
por: Chu, Ying-Hsia, et al.
Publicado: (2015)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
por: Jaruskova, Monika, et al.
Publicado: (2017)

ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib
por: VIVONA, DOUGLAS, et al.
Publicado: (2014)

ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy
por: Bedewy, Ahmed M. L., et al.
Publicado: (2019)

OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib
por: Kim, Yeo-Kyeoung, et al.
Publicado: (2014)

Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients
por: Rinaldi, Ikhwan, et al.
Publicado: (2019)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression
por: Jin, Jing, et al.
Publicado: (2018)

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
por: Chuah, Charles T., et al.
Publicado: (2014)

Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes
por: Venuto, Rocco C., et al.
Publicado: (2015)

Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
por: Gardner, Erin R, et al.
Publicado: (2009)

Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours
por: Tantuan, Sandhya Sreenivasan, et al.
Publicado: (2018)

Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa
por: Jacobs, Clifford, et al.
Publicado: (2014)

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
por: Skoglund, Karin, et al.
Publicado: (2013)

Association between ABCB1 polymorphisms and haplotypes and Alzheimer’s disease: a meta-analysis
por: Zhong, Xin, et al.
Publicado: (2016)

The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response
por: Ningrum, Vitarani Dwi Ananda, et al.
Publicado: (2022)

Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis
por: Dalle Fratte, Chiara, et al.
Publicado: (2023)

Targeting SOS1 overcomes imatinib resistance with BCR-ABL independence through uptake transporter SLC22A4 in CML
por: Liu, Yanjun, et al.
Publicado: (2021)

VKORC1 Pharmacogenetics and Pharmacoproteomics in Patients on Warfarin Anticoagulant Therapy: Transthyretin Precursor as a Potential Biomarker
por: Saminathan, Ramasamy, et al.
Publicado: (2010)

ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients
por: Frankfort, Suzanne V, et al.
Publicado: (2006)

MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia
por: Lardo, Mabel, et al.
Publicado: (2015)

ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
por: Barratt, Daniel T, et al.
Publicado: (2012)

A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects
por: Lee, Ko-Onn, et al.
Publicado: (2016)

Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy—Modulators of Cellular Entry or Pharmacokinetics?
por: Brecht, Karin, et al.
Publicado: (2020)

Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients
por: Faraji, Abolfazl, et al.
Publicado: (2016)

Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The Impact of ABCB1 and CES1 Polymorphisms on Dabigatran Pharmacokinetics in Healthy Chinese Subjects
por: Liu, Yue, et al.
Publicado: (2021)

Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1
por: Degraeve, Alexandra L., et al.
Publicado: (2023)

Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients
por: Chen, Peixian, et al.
Publicado: (2022)

Genetic Variation in CYP2D6 and SLC22A1 Affects Amlodipine Pharmacokinetics and Safety
por: Soria-Chacartegui, Paula, et al.
Publicado: (2023)

Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia
por: Maia, Raquel C., et al.
Publicado: (2018)

Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study
por: Boyer, Thomas, et al.
Publicado: (2019)

An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
por: Vandell, A G, et al.
Publicado: (2018)

Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
por: Fujiwara, Yutaka, et al.
Publicado: (2016)

The Effect of Apigenin on Pharmacokinetics of Imatinib and Its Metabolite N-Desmethyl Imatinib in Rats
por: Liu, Xian-yun, et al.
Publicado: (2013)

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans
por: Dong, C, et al.
Publicado: (2009)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Beyond Single Nucleotide Polymorphisms: CYP3A5(∗)3(∗)6(∗)7 Composite and ABCB1 Haplotype Associations to Tacrolimus Pharmacokinetics in Black and White Renal Transplant Recipients
por: Brazeau, Daniel A., et al.
Publicado: (2020)

Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)

The Interaction between Four Polymorphisms and Haplotype of ABCB1, the Risk of Non-Small Cell Lung Cancer, and the Disease Phenotype
por: Jeleń, Agnieszka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l154l38b5mau8tq447egnrj4d8